title: Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.
abstract: The impact of chronic hepatitis C (HCV) worldwide is expected to increase as the population infected with HCV ages and more undiagnosed individuals are identified and linked to care through nation-wide initiatives. The development of interferon-free regimens involving the use of direct-acting antiviral agents, which disrupt key steps in viral replication, has revolutionized the treatment of chronic HCV infection. However, there remains a great medical need for HCV therapy that is of shorter duration, all-oral, with a high barrier to resistance, and highly effective for all patient populations including those with end-stage renal disease (ESRD) and cirrhosis. Grazoprevir, an HCV NS3/4A protease inhibitor and elbasvir, an NS5A inhibitor, have broad in vitro activity against most HCV genotypes and retain in vitro activity against many clinically relevant resistance-associated variants. The once daily regimen is well-tolerated and highly efficacious across wide-ranging patient populations including those with ESRD on hemodialysis.
authors.affiliation: a Metabolic Liver Disease Program , Texas Liver Institute , Austin , TX , USA.|b University of Texas Health Sciences Center San Antonio (UTHSCSA) , San Antonio , TX , USA.|c Dell Medical School , UT Austin , Austin , TX , USA.
authors.forename: Carmen
authors.initials: C
authors.lastname: Landaverde
authors.affiliation: b University of Texas Health Sciences Center San Antonio (UTHSCSA) , San Antonio , TX , USA.|c Dell Medical School , UT Austin , Austin , TX , USA.|d Regenerative Liver and Neoplasia , Texas Liver Institute , Austin , TX , USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Wells
authors.affiliation: e Texas Liver Institute , Austin , TX , USA.
authors.forename: Rebekah
authors.initials: R
authors.lastname: Hamner
authors.affiliation: e Texas Liver Institute , Austin , TX , USA.
authors.forename: Janie L
authors.initials: JL
authors.lastname: Goldstein
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001572:Benzofurans / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004338:Drug Combinations; D004347:Drug Interactions; D016174:Hepacivirus / Q000187:drug effects* / Q000201:enzymology / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011810:Quinoxalines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D001572:Benzofurans; D004338:Drug Combinations; D007093:Imidazoles; D011480:Protease Inhibitors; D011810:Quinoxalines; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C000611265:elbasvir-grazoprevir drug combination; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase
keywords: Hepatitis C; direct-acting antiviral agents; elbasvir; grazoprevir; resistance-associated variants